Switch theme
Sign up to access all valuation multiples
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
1988
15.1K+
LTM Revenue $13.8B
LTM EBITDA $5.1B
$47.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Regeneron Pharmaceuticals has a last 12-month revenue (LTM) of $13.8B and a last 12-month EBITDA of $5.1B.
In the most recent fiscal year, Regeneron Pharmaceuticals achieved revenue of $14.2B and an EBITDA of $5.3B.
Regeneron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Regeneron Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.8B | XXX | $14.2B | XXX | XXX | XXX |
| Gross Profit | $13.0B | XXX | $12.2B | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $5.1B | XXX | $5.3B | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBIT | $4.7B | XXX | $4.0B | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 28% | XXX | XXX | XXX |
| Net Profit | $4.8B | XXX | $4.4B | XXX | XXX | XXX |
| Net Margin | 35% | XXX | 31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Regeneron Pharmaceuticals's stock price is $490.
Regeneron Pharmaceuticals has current market cap of $52.9B, and EV of $47.3B.
See Regeneron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.3B | $52.9B | XXX | XXX | XXX | XXX | $41.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Regeneron Pharmaceuticals has market cap of $52.9B and EV of $47.3B.
Regeneron Pharmaceuticals's trades at 3.3x EV/Revenue multiple, and 8.9x EV/EBITDA.
Equity research analysts estimate Regeneron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Regeneron Pharmaceuticals has a P/E ratio of 11.1x.
See valuation multiples for Regeneron Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $52.9B | XXX | $52.9B | XXX | XXX | XXX |
| EV (current) | $47.3B | XXX | $47.3B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.3x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 10.1x | XXX | 11.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.1x | XXX | 12.0x | XXX | XXX | XXX |
| EV/FCF | 8.9x | XXX | 13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRegeneron Pharmaceuticals's last 12 month revenue growth is -1%
Regeneron Pharmaceuticals's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.5M for the same period.
Regeneron Pharmaceuticals's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Regeneron Pharmaceuticals's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Regeneron Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | -9% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regeneron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Regeneron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Regeneron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Regeneron Pharmaceuticals founded? | Regeneron Pharmaceuticals was founded in 1988. |
| Where is Regeneron Pharmaceuticals headquartered? | Regeneron Pharmaceuticals is headquartered in United States of America. |
| How many employees does Regeneron Pharmaceuticals have? | As of today, Regeneron Pharmaceuticals has 15.1K+ employees. |
| Who is the CEO of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's CEO is Dr. Leonard S. Schleifer,M.D.,PhD. |
| Is Regeneron Pharmaceuticals publicy listed? | Yes, Regeneron Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals trades under REGN ticker. |
| When did Regeneron Pharmaceuticals go public? | Regeneron Pharmaceuticals went public in 1991. |
| Who are competitors of Regeneron Pharmaceuticals? | Similar companies to Regeneron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's current market cap is $52.9B |
| What is the current revenue of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's last 12 months revenue is $13.8B. |
| What is the current revenue growth of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Regeneron Pharmaceuticals? | Current revenue multiple of Regeneron Pharmaceuticals is 3.4x. |
| Is Regeneron Pharmaceuticals profitable? | Yes, Regeneron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's last 12 months EBITDA is $5.1B. |
| What is Regeneron Pharmaceuticals's EBITDA margin? | Regeneron Pharmaceuticals's last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Regeneron Pharmaceuticals? | Current EBITDA multiple of Regeneron Pharmaceuticals is 9.3x. |
| What is the current FCF of Regeneron Pharmaceuticals? | Regeneron Pharmaceuticals's last 12 months FCF is $5.3B. |
| What is Regeneron Pharmaceuticals's FCF margin? | Regeneron Pharmaceuticals's last 12 months FCF margin is 39%. |
| What is the current EV/FCF multiple of Regeneron Pharmaceuticals? | Current FCF multiple of Regeneron Pharmaceuticals is 8.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
